According to the latest results from Gallup’s survey, self-reported obesity has started to fall, declining by nearly 3 points to 37 percent in 2025. The self-repo ...

Determined to "live as a healthy father," I administered my first injection of the lowest dose (2.5 mg) of the weight loss ...

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is gen ...

Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...

Pre-diabetes offers a crucial chance to reset metabolism and prevent full diabetes. Longevity doctor Dr. Vassily Eliopoulos ...

and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is ...

More than 67 million Americans take melatonin, which can be used to treat insomnia, and analysts predict sales of the ...

An AI tool showed noninferiority to senior endocrinology physicians in insulin titration for hospitalized patients with type 2 diabetes. About 99% of AI-based insulin recommendations were adopted by ...

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic ...

Sephience (sepiapterin) is a prescription drug that’s used along with a special diet to help lower phenylalanine levels in adults and certain children with phenylketonuria (PKU). Sephience comes as an ...